DP

Dennis Paul, Ph.D.

Chief Science Officer

Oleander Medical Technologies

Therapeutic Areas

Oleander Medical Technologies Pipeline

DrugIndicationPhase
Targeted Osmotic Lysis (TOL)Advanced/Invasive CancersPre-clinical